|
|
α-galactosylceramide |
|
Vaxjo ID |
227 |
|
Vaccine Adjuvant Name |
α-galactosylceramide |
|
Adjuvant VO ID |
VO_0005757
|
|
Description |
A glycolipid that activates invariant natural killer T (iNKT) cells by binding CD1d on APCs, enhancing humoral and cellular immune responses |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
Glycolipid with ceramide backbone and α-linked galactose |
|
Molecular Weight |
~859.27 g/mol |
|
Preparation |
Dissolved in vehicle (e.g., polysorbate or PBS), administered subcutaneously or intravenously with antigens |
|
Dosage |
1–4 μg per mouse subcutaneously, co-administered with antigen |
|
Function |
we used a murine Clostridioides difficile immunization and challenge model to evaluate Alum (Alhydrogel™), α-galactosylceramide (α-GC), and one of its analogs 7DW8-5 singly and in combination as vaccine adjuvants. |
|
Safety |
Well-tolerated alone; combination with Alum can cause transient hepatotoxicity (reversible ALT elevation) |
| References |
Lang et al., 2021: Lang GA, Norman K, Amadou Amani S, Shadid TM, Ballard JD, Lang ML. Use of a Clostridioides difficile Murine Immunization and Challenge Model to Evaluate Single and Combination Vaccine Adjuvants Consisting of Alum and NKT Cell-Activating Ligands. Frontiers in immunology. 2021; 12; 818734. [PubMed: 35095921].
|
|
